Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
Hosted on MSN2h
Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for Investors
Vertex Pharmaceuticals (VRTX) closed the latest trading day at $402.70, indicating a +0.84% change from the previous session's end. This change outpaced the S&P 500's 0.43% loss on the day. At the ...
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains
Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.84% higher to $402.70 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.43 ...
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...
Shareholders that lost money on Vertex Pharmaceuticals Incorporated(VRTX) should contact Levi & Korsinsky about Securities Fraud Investigation - VRTX
NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
Different genetic mutations cause different problems with this particular protein -- so CFTR modulators generally don't work ...
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
Shares of Vertex Pharmaceuticals Inc. VRTX slid 0.46% to $408.76 Friday, on what proved to be an all-around rough trading ...
AOL12d
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?
On Thursday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced results from its Phase 2 study of suzetrigine for ...
Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst
Vertex Pharmaceuticals announced FDA approval for Alyftrek, which expands the company's CF franchise to address around 6,000 ...
Vertex Pharmaceuticals price target lowered to $460 from $550 at Truist
Truist analyst Joon Lee lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $460 from $550 and keeps a Buy ...
The Motley Fool5d
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals is trying to diversify its product portfolio. One of the programs it's working on aims to treat pain in a few contexts. There's reason to believe that it won't be effective ...
Yahoo Finance5d
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...